Insider Confidence: Recent filings show a director acquiring $570,000 in shares at $10.64, with the stock closing near $12.50 shortly after. This move aligns with broader market attention on the company's pipeline advancements.
Market Momentum: Shares have climbed sharply over recent months, posting intraday gains exceeding 17 percent amid reports of partnerships and clinical progress. Observers note the potential for sustained interest tied to upcoming milestones in drug development.
Investor Outlook: Discussions highlight the stock's trajectory from lower levels, with some drawing parallels to high-growth names while emphasizing ongoing execution risks in the biotech sector. Overall views reflect measured optimism around long-term catalysts.
Note: This discussion summary was generated from an AI condensation of post data.
AbCellera Biologics Insider Trading Activity
AbCellera Biologics insiders have traded $ABCL stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABCL stock by insiders over the last 6 months:
- MICHAEL R HAYDEN has made 2 purchases buying 100,000 shares for an estimated $1,051,475 and 0 sales.
- HOLDINGS LTD. THERMOPYLAE has made 2 purchases buying 215,457 shares for an estimated $711,004 and 0 sales.
- ANDREW BOOTH (Chief Financial Officer) has made 2 purchases buying 79,800 shares for an estimated $529,596 and 0 sales.
- JOHN S. MONTALBANO has made 2 purchases buying 30,000 shares for an estimated $205,700 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AbCellera Biologics Hedge Fund Activity
We have seen 75 institutional investors add shares of AbCellera Biologics stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC removed 3,516,085 shares (-93.7%) from their portfolio in Q2 2026, for an estimated $27,601,267
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,258,270 shares (-43.0%) from their portfolio in Q2 2026, for an estimated $25,577,419
- BANK OF AMERICA CORP /DE/ added 3,141,603 shares (+104.7%) to their portfolio in Q2 2026, for an estimated $24,661,583
- JEFFERIES FINANCIAL GROUP INC. removed 2,746,200 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $21,557,670
- BAKER BROS. ADVISORS LP added 2,736,200 shares (+9.0%) to their portfolio in Q2 2026, for an estimated $21,479,170
- UBS GROUP AG removed 2,338,419 shares (-55.6%) from their portfolio in Q2 2026, for an estimated $18,356,589
- ALYESKA INVESTMENT GROUP, L.P. removed 2,065,528 shares (-79.7%) from their portfolio in Q2 2026, for an estimated $16,214,394
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AbCellera Biologics Price Targets
Multiple analysts have issued price targets for $ABCL recently. We have seen 3 analysts offer price targets for $ABCL in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Robert Wasserman from Benchmark set a target price of $11.0 on 07/07/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $7.0 on 05/05/2026
- Debanjana Chatterjee from Jones Trading set a target price of $11.0 on 04/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
